SEC Form 4 · accession 0000914190-18-000400
REGENERX BIOPHARMACEUTICALS INC · RGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Allan L Goldstein
Director
Period of report
Sep 11, 2018
Accepted (ET)
Sep 13, 2018 · 5:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000707511
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 11, 2018 | C | 229,803 | $0.06 | A | 1,731,881 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Convertible Promissory Note (right to buy)F1 | $0.06 | Sep 11, 2018 | C | 229,803 | D | Sep 12, 2013 | Sep 11, 2018 | Common Stock | 229,803 | 0 | D |
| Convertible Promissory Note (right to buy)F2 | $0.06 | holding | — | — | — | Jan 7, 2014 | Jan 6, 2019 | Common Stock | 166,667 | — | D |
| Stock Option (right to buy)F3 | $0.57 | holding | — | — | — | — | Apr 10, 2019 | Common Stock | 71,942 | 71,942 | D |
| Stock Option (right to buy)F3 | $0.16 | holding | — | — | — | — | Dec 2, 2018 | Common Stock | 80,135 | 80,135 | D |
| Stock Option (right to buy)F3 | $0.14 | holding | — | — | — | — | Jan 24, 2019 | Common Stock | 300,000 | 300,000 | D |
| Stock Option (right to buy)F3 | $0.16 | holding | — | — | — | — | Apr 3, 2019 | Common Stock | 35,000 | 35,000 | D |
| Stock Option (right to buy)F3 | $0.21 | holding | — | — | — | — | Mar 25, 2021 | Common Stock | 450,000 | 450,000 | D |
| Stock Option (right to buy)F3 | $0.36 | holding | — | — | — | — | Jun 30, 2022 | Common Stock | 250,000 | 250,000 | D |
| Stock Option (right to buy)F4 | $0.64 | holding | — | — | — | — | Mar 16, 2023 | Common Stock | 200,000 | 200,000 | D |
| Stock Option (right to buy)F5 | $0.28 | holding | — | — | — | — | Sep 1, 2027 | Common Stock | 150,000 | 150,000 | D |
| Stock Option (right to buy)F6 | $0.21 | holding | — | — | — | — | Jul 17, 2028 | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1The Convertible Promissory Note in the principal amount of $11,000 accrued $2,788.19 in interest and both principal and interest were converted into 229,803 shares of common stock at a conversion price of $0.06 per share.
- F2Represents the shares of common stock issuable upon conversion of the Convertible Promissory Note.
- F3100% vested.
- F450,000 shares vest on each of 3/16/16, 3/16/17, 3/16/18 and 3/16/19.
- F537,500 shares vest on each of 9/1/17, 9/1/18, 9/1/19 and 9/1/20.
- F662,500 shares vest on each of 7/17/18, 7/17/19, 7/17/20 and 7/17/21.